SEC Form 4 · accession 0001179022-19-000027

GALECTIN THERAPEUTICS INC · GALT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Feb 21, 2019

Accepted (ET)

Feb 25, 2019 · 4:38 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001133416

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Feb 21, 2019	S	7,000	$6.00	D	13,581	D
Common Stock	Feb 21, 2019	M	43,326	$2.39	A	56,907	D
Common Stock^F2	Feb 21, 2019	S	43,326	$6.0247	D	13,581	D
Common Stock	Feb 22, 2019	M	859	$2.39	A	14,440	D
Common Stock^F3	Feb 22, 2019	S	859	$6.0244	D	13,581	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock option (right to buy)^F4	$2.39	Feb 21, 2019	M	43,326	D	—	Dec 15, 2026	Common Stock	43,326	33,924	D
Stock option (right to buy)^F4	$2.39	Feb 22, 2019	M	859	D	—	Dec 15, 2026	Common Stock	859	33,065	D

F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.
F2The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3The shares were sold in multiple transactions at prices ranging from $6.00 to $6.02. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4The options vested 100% on December 14, 2018.